Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 6 Leukemia, Myeloid, Acute 4 Thyroid Neoplasms 2 Neoplasms 2 Hepatoblastoma 2 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Squamous Cell Carcinoma of Head and Neck 1 Rhabdomyosarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Melanoma 1 Gastrointestinal Stromal Tumors 1 Fibrolamellar hepatocellular carcinoma 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma 1

Interventions

Cyclophosphamide 10 Magnetic Resonance Spectroscopy 8 Temozolomide 6 Biopsy 6 dinutuximab 5 X-Rays 5 Topotecan 5 Specimen Handling 5 Phantoms, Imaging 5 Nuclear Medicine Department, Hospital 5 Irinotecan 5 Etoposide 3 Colony-Stimulating Factors 3 ulixertinib 2 tipifarnib 2 selpercatinib 2 sargramostim 2 pembrolizumab 2 palbociclib 2 naxitamab 2 larotrectinib 2 ivosidenib 2 fludarabine phosphate 2 fludarabine 2 etoposide phosphate 2 erdafitinib 2 ensartinib 2 Lenalidomide 2 Isotretinoin 2 Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neuroblastoma × Sorafenib × Clear all

NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡